On January 22nd 2018, Precision BioSciences CEO and Co-founder Matt Kane will participate in the Silicon Valley Precision Medicine World Conference (PMWC), sharing his insights as part of Emmanuelle Charpentier’s CRISPR technology session. He discussed features that distinguish Precision’s ARCUS platform from CRISPR and other gene editing technologies in an interview with PMWC.

Read Matt’s interview on the PWMC blog

About Precision BioSciences

Precision BioSciences is dedicated to improving life. Our mission is to cure genetic disease, overcome cancer, and feed the planet. We are achieving this with ARCUS, the first therapeutic-grade, naturally-derived genome editing system that uniquely combines the specificity and efficacy required to overcome life’s greatest genetic challenges.

Contact Precision BioSciences

Heather King
+1 919-314-5512